Author: Tré-Hardy, Marie; Cupaiolo, Roberto; Wilmet, Alain; Antoine-Moussiaux, Thomas; Vecchia, Andrea Della; Horeanga, Alexandra; Papleux, Emmanuelle; Vekemans, Marc; Beukinga, Ingrid; Blairon, Laurent
Title: Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected Cord-id: 3y8ugfys Document date: 2021_8_23
ID: 3y8ugfys
Snippet: OBJECTIVES: : Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3(rd) dose could be necessary. METHODS: : Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months
Document: OBJECTIVES: : Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3(rd) dose could be necessary. METHODS: : Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire. RESULTS: : We report here a marked and statistically significant antibody decrease (P <0.0001) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort. CONCLUSIONS: : In a supply-limited environment, our results plead for reserving the 3(rd) dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
Search related documents:
Co phrase search for related documents- additional long term study and long term study: 1, 2, 3
- liver disease and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- liver disease and low mortality rate: 1
- liver disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- liver disease diabetes and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9
- liver disease diabetes and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- liver disease diabetes cardiovascular disease and logistic regression: 1
- liver disease diabetes cardiovascular disease and lung disease: 1
- logistic regression and long term study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- logistic regression and low mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
- logistic regression and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- long term study and low mortality rate: 1
- long term study and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
- low mortality rate and lung disease: 1
Co phrase search for related documents, hyperlinks ordered by date